Continuous Versus Single Injection Adductor Canal Blocks for Outpatient Total Knee Arthroplasty
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Jan 15, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain relief for patients having total knee replacement surgery. Specifically, it aims to compare a continuous nerve block, which provides ongoing pain relief, to a single injection nerve block, which delivers pain relief in one shot. Researchers want to see which method leads to less pain, less need for pain medication, and better progress in physical therapy during the first week after surgery.
To participate in the trial, you need to be an adult at least 18 years old, undergoing your first knee replacement surgery, and weigh more than 50 kg to ensure safety. You cannot take strong pain medications regularly or have certain medical conditions that could complicate the surgery. If you join the trial, you’ll be randomly assigned to receive either the continuous nerve block or the single injection before your surgery. The trial is not yet recruiting participants, but it will help doctors understand the best way to manage pain after knee surgery, which can improve recovery experiences for many patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult participants of at least 18 years of age
- • 2. Undergoing a primary, unilateral, total knee arthroplasty
- • 3. Planned single-injection adductor canal nerve block
- • 4. Weight \> 50 kg (to minimize the risk of local anesthetic toxicity)
- Exclusion Criteria:
- • 1. chronic opioid or tramadol use: daily oxycodone equivalents \> 20 mg for \> 4 weeks
- • 2. neuro-muscular deficit of the surgical limb
- • 3. moderate pain (NRS \> 3) in an anatomic location other than the surgical site
- • 4. planned hospital admission following surgery
- • 5. history of opioid misuse
- • 6. those who lack capacity to complete informed consent
- • 7. inability to contact the investigators during the treatment period, and vice versa (e.g., lack of telephone access)
- • 8. incarceration
- • 9. pregnancy
- • 10. allergy to amide local anesthetics
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Jolla, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported